Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face ...

The proposed UK assisted dying law may be delayed until 2029, raising doubts about its future. Novo Nordisk's shares tumble ...

Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump administration’s proposed tariffs on pharmaceutical goods could cause ...

In the midst of tariffs threatened by the US and counter-tariffs by other countries, Danish healthcare company Novo Nordisk’s top management has cautioned of possible price increases and ...

Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s blockbuster diabetes and weight loss drugs ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Novo Nordisk’ chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes ...